
1. malar j. 2017 sep 29;16(1):390. doi: 10.1186/s12936-017-2039-x.

daf-shielded baculovirus-vectored vaccine enhances protection malaria
sporozoite challenge mice.

iyori m(1), yamamoto ds(2), sakaguchi m(3), mizutani m(1), ogata s(1), nishiura
h(1), tamura t(1), matsuoka h(2), yoshida s(4).

author information: 
(1)laboratory vaccinology applied immunology, kanazawa university school
of pharmacy, first natural science building 1a219, kakuma-machi, kanazawa,
920-1192, japan.
(2)division medical zoology, department infection immunity, jichi
medical university, shimotsuke, tochigi, japan.
(3)central laboratory, institute tropical medicine (nekken), nagasaki
university, sakamoto, nagasaki, japan.
(4)laboratory vaccinology applied immunology, kanazawa university school
of pharmacy, first natural science building 1a219, kakuma-machi, kanazawa,
920-1192, japan. shigeto@p.kanazawa-u.ac.jp.

background: previous studies shown baculovirus-vectored vaccine
based "baculovirus dual expression system (bdes)" effective vaccine 
delivery platform malaria. however, point weakness remaining use 
this vaccine platform vivo concerns viral inactivation serum complement. in
an effort achieve complement resistance, gene encoding human
decay-accelerating factor (hdaf) incorporated bdes malaria vaccine
expressing plasmodium falciparum circumsporozoite protein (pfcsp).
results: newly-developed bdes vaccine, designated bdes-spfcsp2-spider,
effectively displayed hdaf pfcsp surface viral envelope,
resulting complement resistance vitro vivo. importantly, upon
intramuscular inoculation mice, bdes-spfcsp2-spider vaccine higher
protective efficacy (60%) control vaccine bdes-spfcsp2-spier
(30%) challenge transgenic plasmodium berghei sporozoites expressing
pfcsp.
conclusion: daf-shielded bdes-vaccines offer great potential development a
new malaria vaccine platform sporozoite challenge.

doi: 10.1186/s12936-017-2039-x 
pmcid: pmc5622557
pmid: 28962615  [indexed medline]

